Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

2024 Updates on Myeloproliferative Neoplasms, PV, and ET

Integrity CE

A. Tefferi

2024 Updates in PV/ET

University of Colorado Division of Hematology

B. McMahon

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

What to Do When Patch Testing is Negative?

American Contact Dermatitis Society (ACDS)

M. Montanez-Wiscovich

Experts Discuss How They Choose 2L Therapy in MF

MyCancerHaven

R. Vij, P. Bose

Current Management of Accelerated/Blast-Phase MPNs

UChicago Medicine

A. Patel

Experts Discuss Their Current Approach to Treating MF

MyCancerHaven

R. Vij, A. Yacoub

Key Updates in AML, MDS, & MF From ASH

Memorial Sloan Kettering Cancer Center

A. Goldberg

Top 5 Impactful MPN Abstracts From Summer Conferences

Insights from 2024 EHA Annual Meeting

P. Bose

Counseling Patients With Newly Diagnosed PV or ET

Krisstina Gowin

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Implicat…

Insights from 2023 ASH Annual Meeting

D. Tremblay

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

Ruben Mesa

Real-World Data of Ruxolitinib in Myelofibrosis Including Patients W…

Paola Guglielmelli